David H. Aggen, MD, PhD, Petros Grivas, MD, PhD, and Neal Shore, MD, FACS, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in bladder cancer presented during the 2025 ESMO Congress.
Evan T. Hall, MD, MPhil, discusses the limited potential for immunotherapy rechallenge in patients with RCC and challenges with later-line RCC management.
Petros Grivas, MD, PhD, details questions and considerations for integrating perioperative durvalumab plus neoadjuvant chemotherapy into MIBC management.
Sara A. Hurvitz, MD, FACP, offers insight on the use of (neo)adjuvant therapies in HER2-positive early breast cancer, and how to best optimize treatment.
Gentry King, MD, discusses positive and negative outcomes following the phase 3 CELESTIAL and COSMIC-312 trials in patients with hepatocellular carcinoma.
Evorpacept plus TRP produced superior ORR, DOR, and PFS outcomes vs TRP alone in patients with HER2-positive gastric or gastroesophageal junction cancer.
E. Gabriela Chiorean, MD, FASCO, discusses exciting targeted therapies in the GI space and topics to be discussed at the School of Gastrointestinal Oncology meeting.
Rahul Banerjee, MD, FACP, discusses treatment de-escalation strategies with the use of bispecific antibodies in patients with relapsed multiple myeloma.
Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.
Rahul Banerjee, MD, FACP, discusses criteria utilized in deciding between treatment with bispecific antibodies and CAR T-cell therapy in multiple myeloma.